Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0203 | 0.5 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0203 | 0.5 | 0.5 |
Chlamydia trachomatis | SWIB complex protein | 0.0203 | 0.5 | 0.5 |
Brugia malayi | brahma associated protein 60 kDa | 0.0203 | 0.5 | 0.5 |
Echinococcus granulosus | Upstream activation factor subunit UAF30 | 0.0203 | 0.5 | 0.5 |
Echinococcus multilocularis | Upstream activation factor subunit UAF30 | 0.0203 | 0.5 | 0.5 |
Schistosoma mansoni | brg-1 associated factor | 0.0203 | 0.5 | 0.5 |
Toxoplasma gondii | SWIB/MDM2 domain-containing protein | 0.0203 | 0.5 | 0.5 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0203 | 0.5 | 0.5 |
Toxoplasma gondii | DNA topoisomerase domain-containing protein | 0.0203 | 0.5 | 0.5 |
Loa Loa (eye worm) | brahma associated protein | 0.0203 | 0.5 | 0.5 |
Plasmodium vivax | SWIB/MDM2 domain-containing protein, putative | 0.0203 | 0.5 | 0.5 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0203 | 0.5 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.0203 | 0.5 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0203 | 0.5 | 0.5 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0203 | 0.5 | 0.5 |
Loa Loa (eye worm) | SWIB/MDM2 domain-containing protein | 0.0203 | 0.5 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0203 | 0.5 | 0.5 |
Echinococcus granulosus | SWI:SNF matrix associated | 0.0203 | 0.5 | 0.5 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0203 | 0.5 | 0.5 |
Onchocerca volvulus | 0.0203 | 0.5 | 0.5 | |
Chlamydia trachomatis | DNA topoisomerase I | 0.0203 | 0.5 | 0.5 |
Brugia malayi | SWIB/MDM2 domain containing protein | 0.0203 | 0.5 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0203 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | > 20 uM | PUBCHEM_BIOASSAY: SAR analysis of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1778, AID1785, AID1786, AID1966, AID2133, AID2136, AID2285, AID2495] | ChEMBL. | No reference |
IC50 (functional) | > 32 uM | PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420] | ChEMBL. | No reference |
IC50 (functional) | > 32 uM | PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the DOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785] | ChEMBL. | No reference |
IC50 (functional) | > 32 uM | PUBCHEM_BIOASSAY: SAR analysis of Antagonists of the Kappa Opioid Receptor (KOR) using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.